UBS downgraded Biohaven (BHVN) to Neutral from Buy with a price target of $11, down from $26. The firm says the company’s “multiple” research and development and regulatory setbacks have lowered confidence on the viability of its remaining pipeline programs. Most of the immediate value in Biohaven’s pipeline comes from Kv7, but the company is two years behind competitor Xenon in the primary indication, the analyst tells investors in a research note. UBS sees a balanced risk/reward for the shares into the upcoming pipeline catalysts.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Cautious Hold Rating on Biohaven Ltd. Amidst R&D Setbacks and Competitive Challenges
- Biohaven price target lowered to $15 from $47 at JPMorgan
- Biohaven call volume above normal and directionally bullish
- Biohaven price target lowered to $26 from $54 at Morgan Stanley
- Strategic Adjustments and Future Potential: Biohaven Ltd. Receives Buy Rating Amidst Regulatory Challenges